Cathie Wood, founder of Ark Invest, strategically seizes opportunities by investing in innovative technology of the future. Her flagship Ark Innovation fund has climbed more than 80% over the past year. Wood recently added more shares of CRISPR Therapeutics and Intellia Therapeutics, both biotech companies specializing in gene editing. CRISPR Therapeutics has made strides with its first treatment, while Intellia targets hereditary angioedema with promising trial data. Both companies have significant cash reserves and strong growth potential. Wall Street predicts a 50% increase for CRISPR Therapeutics and a whopping 190% gain for Intellia in the next 12 months.

Read more at Nasdaq: Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%